MedTrace Logo

CellMist™ Autologous Cells to Treat Deep Second-Degree Burns

NCT04890574 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2022-03-15

No results posted yet for this study

Summary

The overall purpose of this study is to evaluate the safety of the CellMist™ System in the treatment of deep second degree burns (II°B) in a prospective, multicenter, feasibility pilot study.

Conditions

  • Burns
  • Burns Second Degree
  • Burns Deep Second Degree

Interventions

DEVICE

CellMist™ System

Open Label, Safety and Feasibility

Sponsors & Collaborators

  • RenovaCare, Inc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-26
Primary Completion
2022-10-30
Completion
2022-11-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04890574 on ClinicalTrials.gov